iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Core Insights - iTeos Therapeutics is preparing to report results from multiple clinical programs in 2024, focusing on two validated protein targets for cancer treatment, namely TIGIT and the adenosine pathway [2][9] - The company is advancing belrestotug (EOS-448) targeting the TIGIT protein and inupadenant (EOS-850) targeting the adenosine pathway, with the aim of enhancing drug potency against advanced solid tumors [2][9] Pipeline Developments - Two key phase 2 studies involving belrestotug in combination with dostarlimab are set to report in 2024, targeting non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) [3][9] - The GALAXIES Lung-201 study will focus on 1st-line advanced/metastatic NSCLC patients, while the TIG-006 study will assess the combination in 1st-line PD-L1 positive advanced or metastatic HNSCC patients [3][5] Market Potential - The global NSCLC market is projected to reach $36.9 billion by 2031, while the head and neck cancer drugs market is expected to surpass $3.9 billion by 2030 [3][5] - The studies will target specific patient populations, including those with high PD-L1 expression, which could enhance market opportunities despite competition [3][5] Competitive Landscape - iTeos faces competition from several companies developing anti-TIGIT therapies, including Beigene, Novartis, and Merck, among others [5] - The differentiation of belrestotug lies in its unique design and binding properties, which may provide a competitive edge over existing therapies [5][9] Financial Position - As of September 30, 2023, iTeos Therapeutics reported cash and cash equivalents of $644.9 million, sufficient to fund operations through 2026 and support multiple phase 3 studies [6] - The company has a Sales Agreement with Cowen for an aggregate offering price of $125 million, providing a financial cushion if additional funds are needed [6]